Transperineal Prostate Biopsy
A urologist-led explanation of why the transperineal route matters, when biopsy follows PSA/MRI review, and how infection risk differs from transrectal biopsy.
Board-certified urologist and robotic surgeon
A prostate biopsy decision should not be driven by panic over one PSA number. It should follow a structured review of PSA trend, exam context, risk factors, MRI findings, and whether tissue diagnosis will change the plan. When biopsy is reasonable, the route matters.
Transperineal biopsy samples through cleaned perineal skin rather than through the rectal wall.
The route is important because it reduces exposure to rectal bacteria compared with transrectal biopsy.
MRI-targeted sampling can help direct biopsy toward suspicious areas when imaging supports it.
The goal is the right biopsy for the right patient, not biopsy for every elevated PSA.
Why this belongs under urology
PSA interpretation, MRI review, biopsy route, pathology results, and the decision between surveillance and treatment are urology decisions. Public education should help men ask better questions before they are frightened into the wrong next step.
The patient question to answer
The practical question is not only whether biopsy is needed. It is whether the biopsy route, infection precautions, MRI targeting, and follow-up plan make sense for the patient's risk picture.